{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.8","upperLimit":"17.2","value":"12.4"},{"comment":"Median OS and upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"6.7","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"13.8","upperLimit":"22.1","value":"17.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing(immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG000","title":"Cohort 1: HER2 Overexpressing"},{"description":"Participants with HER2-overexpressing (immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG001","title":"Cohort 1a: HER2 Overexpressing"},{"description":"Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG002","title":"Cohort 2: HER2 Mutated"}],"paramType":"MEDIAN","populationDescription":"Overall survival (OS) was assessed in the Full Analysis Set at data cut-off date of 03 May 2021.","reportingStatus":"POSTED","timeFrame":"From date of enrollment to death from any cause, up to 36 months (data cut-off)","title":"Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)","type":"SECONDARY","unitOfMeasure":"months"}